This segment focuses on the development and commercialization of VICAPSYN, a proprietary product designed to improve outcomes in transplantation therapies and related stem-cell applications. Research and development efforts are directed towards enhancing the efficacy and safety of VICAPSYN in preventing organ rejection and promoting long-term graft survival. The technology involves encapsulating cells to protect them from immune attack and enhance their therapeutic potential. This segment addresses the critical need for improved transplantation outcomes, reducing the reliance on immunosuppressive drugs and improving the quality of life for transplant recipients. Future opportunities include expanding the applications of VICAPSYN to various organ transplant procedures and exploring its potential in regenerative medicine.

This segment is dedicated to the development of VYBRIN, a product based on CXCL12, aimed at preventing post-surgical adhesions in abdominal surgery, coating implantable medical devices to eliminate fibrosis, and promoting wound healing, particularly in diabetic ulcers. Research efforts are focused on optimizing the formulation and delivery of CXCL12 to enhance its anti-fibrotic and wound-healing properties. The technology leverages the natural ability of CXCL12 to attract stem cells and promote tissue regeneration. This segment addresses the significant clinical challenges of post-surgical complications and chronic wounds, offering the potential to reduce patient morbidity, improve surgical outcomes, and accelerate the healing process. Future opportunities include expanding the applications of VYBRIN to other surgical procedures and exploring its potential in treating other fibrotic conditions.